ClinicalTrials.gg
CompletedNCT03747315DEPIST-FMFUpdated Jun 8, 2021

A Diagnostic Test for Familial Mediterranean Fever

An observational study in Familial Mediterranean Fever, sponsored by Hospices Civils de Lyon. Completed at 4 sites in France. Open to participants aged 4 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-08.

Sponsored by Hospices Civils de Lyon · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
107
Ages
4 Years and older
Sex
All
01

Study summary

Familial Mediterranean Fever (FMF) is the most common auto-inflammatory disease (prevalence: 1-5 / 10,000 inhabitants). It is due to mutations of the MEFV gene, encoding variants of the Pyrin inflammasome. Inflammasomes are protein complexes of innate immunity producing pro-inflammatory cytokines (interleukin-1β).

In vitro, preliminary results demonstrated that activation of the Pyrin inflammasome (measured by interleukin-1β concentration) by kinase inhibitors is significantly increased in FMF patients compared to subjects with a similar clinical picture, and healthy controls. In addition, a measure of cell death yielded significant results in differentiating patients from controls.

The investigators hypothesize that this fast and simple functional test can serve as a diagnostic tool for FMF.

02

Conditions studied

  • Familial Mediterranean Fever
03

In context

Familial Mediterranean Fever

61 studies on the registry are indexed under Familial Mediterranean Fever; 27 are open to participants now.

This study's enrollment of 107 is above the median of 89 across 30 observational studies indexed under Familial Mediterranean Fever.

Browse Familial Mediterranean Fever studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,867 studies on the registry; 448 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients with Familial Mediterranean Fever, patients controls with similar symptoms and healthy subjects who donated their blood to the French Blood Establishment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical picture compatible with an Familial Mediterranean Fever and an earlier genetic analysis finding a mutation of the MEFV gene;
  • Newly diagnosed or undergoing follow-up (without criteria of delay or evolutionary stage);
  • In the course of specific or non-specific treatment of the disease or without treatment;
  • For whom a blood test is planned as part of the routine care;
  • Of whom the informed non-opposition has been collected (parental authorization in the case of a minor patient);

Exclusion criteria

Exclusion Criteria:

  • patient under legal protection or under safeguard of justice or any other measures of protection (guardianship, curatorship);
  • Person unable to express his consent;
  • Person in emergency situation, vital or not;
  • Infection known to and / or and / or
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
107 participants (actual)
Patient registry
No

Groups and cohorts

  • Familial Mediterranean Fever (patients)

    Patients with previously confirmed Familial Mediterranean Fever (based on clinical criteria)

    Other: In vitro functional test

  • Control group (patients)

    Patients with symptoms similar to that of Familial Mediterranean Fever (e.g. Behcet disease, Crohn, sepsis..) but without confirmed Familial Mediterranean Fever.

    Other: In vitro functional test

  • Healthy donors

    Patients without symptoms (anonymous blood donors)

    Other: In vitro functional test

Interventions

  • OtherIn vitro functional test

    Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on an additional blood sample (4 ml for children under 12 and 10 ml for children 12 years and older and adults) during a sample for patient care.

  • OtherIn vitro functional test

    Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on samples from healthy subjects who donated their blood to the French Blood Establishment.

06

What researchers measure

Primary outcomes

  1. Differences in interleukin-1bβ levels

    Quantification of the capacity of interleukin-1β concentration measured in primary monocyte supernatants in response to kinase inhibitors, to discriminate Familial Mediterranean Fever subjects from control subjects (healthy subjects and subjects with symptoms similar to those of Familial Mediterranean Fever). Analysis have to be performed Less than 48 hours after blood sampling (only one sampling).

    Time frame: Less than 48 hours

07

Study locations

4 sites
  • Service de néphrologie et rhumatologie pédiatrique, Hôpital Femme Mère Enfant
    Bron, 69500, France
  • Unité Inserm U1111 & Service de Médecine Interne, Hôpital de la Croix-Rousse
    Lyon, 69004, France
  • Service de Médecine Interne, Pavillon O - Hopital Edouard Herriot
    Lyon, 69437, France
  • Service de Médecine Interne et pathologies vasculaires, Batiment 1B, Centre Hospitalier Lyon Sud
    Pierre-Bénite, 69495, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Dec 2020, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2018
First posted
Nov 20, 2018
StartActual
Dec 15, 2018
Primary completionActual
Dec 15, 2020
CompletionActual
Dec 15, 2020
Last update
Jun 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03747315
Responsible party
Sponsor
First posted
Nov 20, 2018
Start date
Dec 15, 2018
Primary completion
Dec 15, 2020
Completion
Dec 15, 2020
Last update
Jun 8, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion